Japan listing includes thalidomide for myeloma
This article was originally published in Scrip
Executive Summary
Japan's Central Social Insurance Medical Council (Chuikyo) has granted reimbursement prices to a group of drugs including Fujimoto Pharmaceutical's thalidomide product Thaled for the orphan indication of refractory multiple myeloma.